Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podejrzenie lub rozpoznanie zaawansowanego/przerzutowego nowotworu złośliwego wielu typów (płuco, skóra, przełyk, szyjka macicy, macica, jelito grube, wątroba i inne) kwalifikującego się do immunoterapii
- •Lub nowotwór nerki bądź pęcherza w stadium III/IV kwalifikujący się do immunoterapii
- •Lub pacjenci planowani do leczenia neoadjuwantowego immunoterapią (rak piersi potrójnie ujemny, rak płuca) przed operacją
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- March 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Mayo Clinic in Arizona
Phoenix, United States
Mayo Clinic in Florida
Jacksonville, United States
Mayo Clinic in Rochester
Rochester, United States
Trial contact
Clinical Trials Referral Office
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.